Marked-up Version to Show Amendments Made to Claims

Claims 1, 2, 9, 10, 11 and 17 have been amended as follows:

--1. A method for treating or preventing stroke in a human subject [wherein the subject is] susceptible to intracranial hemorrhaging, comprising administering [a] to the human subject an effective amount of CD39 polypeptide comprising consecutive amino acids the sequence of which is set forth in [(] SEQ ID NO. 1 [)] or an active polypeptide fragment thereof so as to inhibit [which inhibits] adenosine diphosphate-mediated platelet aggregation or inhibits leukocyte accumulation and/or ATP by increasing adenosine diphosphate catabolism [to the subject] without increasing incidence of intracerebral hemorrhage in the human subject.--

--2. (Amended) The method of claim 1, wherein the active polypeptide fragment of [is] CD39 polypeptide is administered and is a mutated or a truncated form of the CD39 polypeptide.--

--9. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the [its] active polypeptide fragment thereof [occurs] is effected at the onset of stroke in [a] the human subject.--

--10. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the [its] active polypeptide fragment thereof is effected prior to stroke onset in [a] the human subject.

--11. (Amended) The method of claim 1, wherein the administration of the CD39 polypeptide or the [its] active polypeptide fragment thereof [occurs] is effected after [the] stroke onset in [a] the human subject.

--17. (Amended) A method for determining whether a compound inhibits platelet aggregation or leukocyte accumulation by increasing ADP catabolism and does not increase incidence of intracerebral hemorrhage, so as to treat or prevent thrombotic or ischemic disorder[s] in a subject, comprising:

(a) [inducing thrombotic or ischemic disorders in an animal] administering the compound to an animal, which [animal] is [an] a [animal] model for the thrombotic or ischemic disorder[s], before, concurrently with or after step (b);

(b) inducing thrombotic or ischemic disorder in the animal;

[(b)] (c) measuring the [stroke] thrombotic or ischemic disorder outcome and the incidence of intracerebral hemorrhage in the [said] animal;

[(c)] (d) measuring platelet deposition and/or fibrin deposition and/or accumulation of leukocytes in ischemic tissue in the animal [,]; and

[(d)] (e) comparing the [stroke] thrombotic or ischemic disorder outcome [in step B] and the platelet [deposition] and/or fibrin deposition and/or accumulation of leukocytes [with that of the

animal model] in the presence of the compound with in the absence of the compound so as to [identify a] determine whether the compound is capable of treating or preventing thrombotic or ischemic disorder[s] in a subject without increasing the incidence of intracerebral hemorrhage.--